Nicholas Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.76M | Buy |
38,795
+70
| +0.2% | +$15.1K | 0.18% | 104 |
|
|
2026
Q1 | $8.42M | Hold |
38,725
| – | – | 0.17% | 114 |
|
|
2025
Q4 | $8.85M | Hold |
38,725
| – | – | 0.16% | 124 |
|
|
2025
Q3 | $8.97M | Hold |
38,725
| – | – | 0.15% | 133 |
|
|
2025
Q2 | $7.19M | Sell |
38,725
-5,625
| -13% | -$1.05M | 0.12% | 155 |
|
|
2025
Q1 | $9.29M | Buy |
44,350
+3,580
| +9% | +$696K | 0.16% | 125 |
|
|
2024
Q4 | $7.24M | Sell |
40,770
-10
| -0% | -$1.84K | 0.12% | 157 |
|
|
2024
Q3 | $8.05M | Sell |
40,780
-6,085
| -13% | -$1.14M | 0.13% | 149 |
|
|
2024
Q2 | $8.04M | Sell |
46,865
-10,830
| -19% | -$1.79M | 0.13% | 143 |
|
|
2024
Q1 | $10.5M | Hold |
57,695
| – | – | 0.17% | 114 |
|
|
2023
Q4 | $8.94M | Hold |
57,695
| – | – | 0.16% | 120 |
|
|
2023
Q3 | $8.6M | Sell |
57,695
-250
| -0.4% | -$36.7K | 0.17% | 116 |
|
|
2023
Q2 | $7.81M | Hold |
57,945
| – | – | 0.15% | 138 |
|
|
2023
Q1 | $9.23M | Buy |
57,945
+8,065
| +16% | +$1.23M | 0.19% | 120 |
|
|
2022
Q4 | $8.06M | Hold |
49,880
| – | – | 0.17% | 139 |
|
|
2022
Q3 | $6.69M | Buy |
49,880
+30
| +0.1% | +$4.3K | 0.15% | 150 |
|
|
2022
Q2 | $7.64M | Sell |
49,850
-3,540
| -7% | -$541K | 0.17% | 144 |
|
|
2022
Q1 | $8.66M | Hold |
53,390
| – | – | 0.15% | 148 |
|
|
2021
Q4 | $7.23M | Buy |
53,390
+3,540
| +7% | +$418K | 0.12% | 192 |
|
|
2021
Q3 | $5.38M | Buy |
49,850
+5,055
| +11% | +$578K | 0.09% | 210 |
|
|
2021
Q2 | $5.05M | Buy |
44,795
+3,000
| +7% | +$338K | 0.09% | 216 |
|
|
2021
Q1 | $4.52M | Buy |
+41,795
| New | +$4.47M | 0.08% | 215 |
|
|
2017
Q2 | – | Sell |
-540,620
| Closed | -$35.2M | – | 216 |
|
|
2017
Q1 | $35.2M | Sell |
540,620
-175,680
| -25% | -$11M | 0.8% | 48 |
|
|
2016
Q4 | $44.9M | Sell |
716,300
-277,550
| -28% | -$16.9M | 1% | 39 |
|
|
2016
Q3 | $62.7M | Sell |
993,850
-855,395
| -46% | -$55.4M | 1.38% | 29 |
|
|
2016
Q2 | $114M | Buy |
1,849,245
+1,595
| +0.1% | +$97.2K | 2.31% | 15 |
|
|
2016
Q1 | $106M | Buy |
1,847,650
+64,800
| +4% | +$3.61M | 2.15% | 16 |
|
|
2015
Q4 | $106M | Buy |
1,782,850
+53,680
| +3% | +$3.09M | 1.98% | 20 |
|
|
2015
Q3 | $94.1M | Buy |
1,729,170
+22,525
| +1% | +$1.47M | 1.78% | 20 |
|
|
2015
Q2 | $115M | Buy |
1,706,645
+479,770
| +39% | +$31.3M | 2.01% | 11 |
|
|
2015
Q1 | $71.8M | Buy |
+1,226,875
| New | +$74.1M | 1.35% | 30 |
|
Other funds holding ABBV
Nicholas Company's ABBV Position: Q2 2026 in Review
Nicholas Company increased its AbbVie (ABBV) stake by 0.18% in Q2 2026, buying an estimated $15.1K and bringing the position to 38,795 shares worth $9.76M. The position accounts for 0.18% of the portfolio, ranked #104.
Nicholas Company first reported a position in ABBV in Q1 2015 and has held it in 31 quarters since. The position peaked at $115M in Q2 2015. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Nicholas Company held 38,795 shares of AbbVie worth $9.76M as of Q2 2026.
- Nicholas Company bought 70 AbbVie shares in Q2 2026, an estimated $15.1K.
- AbbVie made up 0.18% of Nicholas Company's portfolio in Q2 2026, its #104 holding.
- Nicholas Company first reported a position in AbbVie in Q1 2015 and has held it in 31 quarters since.
- Nicholas Company's AbbVie position peaked at $115M in Q2 2015.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Nicholas Company's 13F filing for Q2 2026, filed 5 Aug 2026.